Assessing patient outcomes following radioiodine

• Research type

  Research Study

• Full title

  Assessing patient outcomes following radioiodine treatment in Graves’ thyrotoxicosis

• IRAS ID

  196073

• Contact name

  Fraser W Gibb

• Contact email

  fraser.gibb@ed.ac.uk

• Sponsor organisation

  NHS Lothian

• Duration of Study in the UK

  0 years, 3 months, 11 days

• Research summary

  Radioiodine is a standard treatment for Graves’ thyrotoxicosis, the commonest cause of an overactive thyroid. In some cases it can be associated with weight gain and the development of thyroid related eye disease. We propose sending out questionnaires to all patients, from our centre, who have received this treatment between 2006 to 2013, to assess health and quality of life outcomes.

• REC name

  North West - Greater Manchester South Research Ethics Committee

• REC reference

  16/NW/0044

• Date of REC Opinion

  19 Jan 2016

• REC opinion

  Favourable Opinion